Literature DB >> 22137680

[Superior oblique myokymia: a report of three cases].

V Thoorens1, C Signolles, S Defoort-Dhellemmes.   

Abstract

INTRODUCTION: Superior oblique myokymia (SOM/MOS) is an under-recognised and probably under-diagnosed disorder. We describe the clinical signs of this condition among three patients. Next, from review of the literature, we suggest an algorithm for diagnosis and treatment. OBSERVATION: Retrospective study of three patients aged 40 to 55 presenting with brief, intermittent monocular episodes of oscillopsia. DISCUSSION: The acute symptomatology of superior oblique myokymia follows a recognizable pattern: it always presents with brief, intermittent monocular vertical oscillopsia and/or vertical diplopia with torsion. The clinical signs are related to a neurogenic hyperexcitability of the superior oblique muscle. Treatment may be medical (carbamazepine, gabapentin, beta-blocker) or surgical. Recent publications report that superior oblique myokymia may result from vascular compression of the trochlear nerve (fourth cranial nerve), which controls the action of the superior oblique muscle, placing this condition in the category of vasculonervous conflicts.
CONCLUSION: Superior oblique myokymia is a relatively poorly known disorder, despite classic pathognomonic symptoms. It is a benign condition, which can nonetheless become incapacitating. It occasionally portends an intracranial pathologic process, which must then be addressed with specific treatment.
Copyright © 2011 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22137680     DOI: 10.1016/j.jfo.2011.05.011

Source DB:  PubMed          Journal:  J Fr Ophtalmol        ISSN: 0181-5512            Impact factor:   0.818


  2 in total

1.  Variable relations of the trochlear nerve with the pontomesencephalic segment of the superior cerebellar artery.

Authors:  Mugurel Constantin Rusu; Alexandra Diana Vrapciu; Jenel Marian Pătraşcu
Journal:  Surg Radiol Anat       Date:  2014-09-19       Impact factor: 1.246

Review 2.  Therapy of Vestibular Paroxysmia, Superior Oblique Myokymia, and Ocular Neuromyotonia.

Authors:  Michael Strupp; Marianne Dieterich; Thomas Brandt; Katharina Feil
Journal:  Curr Treat Options Neurol       Date:  2016-07       Impact factor: 3.598

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.